|Bid||2.3600 x 1000|
|Ask||2.3900 x 800|
|Day's Range||2.3600 - 2.5100|
|52 Week Range||1.3100 - 15.5500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BIAF
SAN ANTONIO, January 24, 2023--bioAffinity Technologies announces publication of the results of its clinical trial for its CyPath® Lung cancer diagnostic in Respiratory Research.
SAN ANTONIO, January 04, 2023--bioAffinity Technologies received Notice of Allowance for a U.S. patent protecting novel compounds for specific delivery of cancer treatments.
Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)